• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Recurrent papillary thyroid carcinoma with pleural metastasis diagnosed by effusion cytology: a report of cases with clinicopathologic correlation.经胸腔积液细胞学检查诊断为复发性甲状腺乳头状癌伴胸膜转移:附病例报告及临床病理相关性分析
Hawaii J Med Public Health. 2015 Feb;74(2):51-6.
2
Malignant pleural effusion from papillary thyroid carcinoma diagnosed by pleural effusion cytology: A case report.经胸腔积液细胞学检查诊断为乳头状甲状腺癌所致恶性胸腔积液:一例报告
Diagn Cytopathol. 2018 Feb;46(2):204-207. doi: 10.1002/dc.23824. Epub 2017 Sep 27.
3
Metastatic papillary thyroid carcinoma in pleural effusion: a case report and review of the literature.胸腔积液中转移性甲状腺乳头状癌:病例报告及文献复习。
J Med Case Rep. 2023 Dec 20;17(1):521. doi: 10.1186/s13256-023-04265-6.
4
[Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].可切除性甲状腺微小乳头状癌的临床病理特征
Zhonghua Zhong Liu Za Zhi. 2017 May 23;39(5):361-366. doi: 10.3760/cma.j.issn.0253-3766.2017.05.008.
5
The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.BRAF V600E突变作为甲状腺乳头状癌预后分层潜在标志物的作用:一项长期随访研究
Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169. Epub 2014 Mar 28.
6
BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.甲状腺乳头状癌细针穿刺活检的BRAF突变分析:对诊断和预后的影响
Acta Cytol. 2011;55(6):563-9. doi: 10.1159/000333272. Epub 2011 Dec 9.
7
Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.原发性和转移性乳头状甲状腺癌中BRAF V600E突变的特异性免疫组化检测
Exp Mol Pathol. 2016 Feb;100(1):236-41. doi: 10.1016/j.yexmp.2016.01.004. Epub 2016 Jan 13.
8
Papillary thyroid carcinoma with extensive squamous dedifferentiation metastatic to the lung: BRAF mutational analysis as a useful tool to rule out tumor to tumor metastasis.广泛鳞状去分化的乳头状甲状腺癌肺转移:BRAF 突变分析作为排除肿瘤间转移的有用工具
Virchows Arch. 2016 Feb;468(2):239-42. doi: 10.1007/s00428-015-1875-8. Epub 2015 Oct 31.
9
Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.具有显著鞋钉样特征的甲状腺乳头状癌的细胞学、临床病理及分子特征:10例病例报告及系统文献综述
Int J Clin Exp Pathol. 2015 Jul 1;8(7):7988-97. eCollection 2015.
10
Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.BRAF基因突变状态、甲状腺乳头状癌原发肿瘤的临床病理特征与淋巴结转移之间的相关性。
Exp Clin Endocrinol Diabetes. 2014 May;122(5):268-72. doi: 10.1055/s-0034-1372624. Epub 2014 May 16.

引用本文的文献

1
Pleural effusion metastatic papillary thyroid carcinoma with dedifferentiation: a case report and review of the literature.伴有去分化的胸膜转移乳头状甲状腺癌:一例报告并文献复习
Front Oncol. 2025 May 28;15:1575821. doi: 10.3389/fonc.2025.1575821. eCollection 2025.
2
Pleural metastases from differentiated thyroid cancer: clinical features and long-term outcomes.分化型甲状腺癌的胸膜转移:临床特征与长期预后
Eur Thyroid J. 2025 Jan 29;14(1). doi: 10.1530/ETJ-24-0147. Print 2025 Feb 1.
3
Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report.乐伐替尼治疗伴恶性胸膜炎的甲状腺癌的策略:一例报告
Gland Surg. 2024 Oct 31;13(10):1846-1852. doi: 10.21037/gs-24-269. Epub 2024 Oct 26.
4
Metastatic papillary thyroid carcinoma in pleural effusion: a case report and review of the literature.胸腔积液中转移性甲状腺乳头状癌:病例报告及文献复习。
J Med Case Rep. 2023 Dec 20;17(1):521. doi: 10.1186/s13256-023-04265-6.
5
Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma.胸腔积液作为转移性甲状腺癌的一种新的预后因素。
Endocr Connect. 2020 Aug;9(8):812-823. doi: 10.1530/EC-20-0193.
6
Pleural fluid due to papillary thyroid cancer.甲状腺乳头状癌所致胸腔积液。
Oncol Lett. 2019 Jul;18(1):962-966. doi: 10.3892/ol.2019.10383. Epub 2019 May 21.

本文引用的文献

1
Aggressive variants of follicular cell-derived thyroid carcinomas: a cytopathologist's perspective.滤泡细胞源性甲状腺癌的侵袭性变体:细胞病理学家的观点
Cancer Cytopathol. 2014 Jul;122(7):484-503. doi: 10.1002/cncy.21417. Epub 2014 Mar 24.
2
Descriptive epidemiology of human thyroid cancer: experience from a regional registry and the "volcanic factor".人类甲状腺癌的描述性流行病学:来自一个区域登记处和“火山因素”的经验。
Front Endocrinol (Lausanne). 2013 Jun 4;4:65. doi: 10.3389/fendo.2013.00065. eCollection 2013.
3
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.BRAF V600E 突变与甲状腺乳头状癌患者死亡率的关系。
JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.
4
UH cancer center hotline: thyroid cancer: rising incidence and ethnic disparities.UH癌症中心热线:甲状腺癌:发病率上升与种族差异
Hawaii J Med Public Health. 2012 Aug;71(8):240-1.
5
BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.甲状腺乳头癌中的 BRAF 突变:致病作用及临床意义。
J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3.
6
The 'rings of fire' and thyroid cancer.“火环”与甲状腺癌。
Hormones (Athens). 2009 Oct-Dec;8(4):249-53. doi: 10.14310/horm.2002.1242.
7
BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.日本人群中甲状腺乳头状癌的BRAF突变:其与高危临床病理特征及患者无病生存期缺乏相关性
Endocr J. 2009;56(1):89-97. doi: 10.1507/endocrj.k08e-208. Epub 2008 Oct 8.
8
BRAF(V600E) mutation and the biology of papillary thyroid cancer.BRAF(V600E)突变与甲状腺乳头状癌的生物学特性
Endocr Relat Cancer. 2008 Mar;15(1):191-205. doi: 10.1677/ERC-07-0212.
9
Fine needle aspiration of follicular variant of papillary thyroid carcinoma presenting with pleural effusion: a case report.细针穿刺诊断伴胸腔积液的甲状腺乳头状癌滤泡变异型:一例报告
Acta Cytol. 2007 Nov-Dec;51(6):911-5. doi: 10.1159/000325869.
10
Time trends and geographic variations for thyroid cancer in New Caledonia, a very high incidence area (1985-1999).新喀里多尼亚(一个甲状腺癌发病率极高的地区)甲状腺癌的时间趋势和地理差异(1985 - 1999年)
Eur J Cancer Prev. 2007 Feb;16(1):62-70. doi: 10.1097/01.cej.0000236244.32995.e1.

经胸腔积液细胞学检查诊断为复发性甲状腺乳头状癌伴胸膜转移:附病例报告及临床病理相关性分析

Recurrent papillary thyroid carcinoma with pleural metastasis diagnosed by effusion cytology: a report of cases with clinicopathologic correlation.

作者信息

Sakamoto Reid I, Sumida Lauren C, Lum Christopher A K, Tauchi-Nishi Pamela S

机构信息

Department of Pathology, The Queen's Medical Center, Honolulu, HI (RIS, CAKL, PST-N).

出版信息

Hawaii J Med Public Health. 2015 Feb;74(2):51-6.

PMID:25755913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4338567/
Abstract

Papillary thyroid carcinoma (PTC) is typically an indolent disease characterized by slow growth and a favorable prognosis. In rare instances, this disease may metastasize to the pleura and manifest as a malignant pleural effusion. We report 3 female patients of Japanese/Okinawan ancestry with a history of PTC who presented with hydrothorax. Cytologic examination in conjunction with immunohistochemical staining enabled a definitive diagnosis of metastatic PTC. Molecular analysis of the mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways demonstrated the presence of the v-raf murine sarcoma viral oncogene homolog B (BRAF)(V600E) mutation in 2 of our 3 patients, with the absence of any other clinically significant mutations in all cases. Further investigation is necessary to elucidate the molecular and environmental mechanisms involved in this aggressive manifestation of PTC.

摘要

甲状腺乳头状癌(PTC)通常是一种生长缓慢、预后良好的惰性疾病。在罕见情况下,这种疾病可能转移至胸膜并表现为恶性胸腔积液。我们报告了3名具有日本/冲绳血统且有PTC病史的女性患者,她们表现为胸腔积液。细胞学检查结合免疫组化染色得以明确诊断转移性PTC。对丝裂原活化蛋白激酶(MAPK)和磷脂酰肌醇3激酶(PI3K)途径的分子分析显示,我们的3例患者中有2例存在v-raf鼠肉瘤病毒癌基因同源物B(BRAF)(V600E)突变,所有病例均未发现任何其他具有临床意义的突变。有必要进一步研究以阐明PTC这种侵袭性表现所涉及的分子和环境机制。